Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SNY

Sanofi ADR

Dec 08 • 04:00PM ET

46.32

Dollar change +0.26
Percentage change 0.56	%

Healthcare • Drug Manufacturers - General • France • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	12.99	EPS (ttm)	3.57	Insider Own	0.03%	Shs Outstand	2.51B	Perf Week	-0.86%
Market Cap	116.16B	Forward P/E	10.71	EPS next Y	4.33	Insider Trans	0.00%	Shs Float	2.51B	Perf Month	1.18%
Income	8.96B	PEG	1.84	EPS next Q	0.94	Inst Own	10.05%	Short Float / Ratio	0.15% / 1.81	Perf Quarter	-14.96%
Sales	45.33B	P/S	2.56	EPS this Y	-2.43%	Inst Trans	-1.65%	Short Interest	3.73M	Perf Half Y	-9.60%
Book/sh	31.66	P/B	1.46	EPS next Y	-1.12%	ROA	6.79%	Target Price	55.51	Perf Year	-3.38%
Cash/sh	3.48	P/C	13.32	EPS next 5Y	7.07%	ROE	11.68%	52W Range	42.63 - 57.82	Perf YTD	-4.36%
Dividend	1.95	P/FCF	14.22	EPS past 5Y	15.72%	ROI	9.26%	52W High	-19.89%	Beta	0.60
Dividend %	4.21%	Quick Ratio	0.81	Sales past 5Y	2.74%	Gross Margin	62.86%	52W Low	8.66%	ATR	0.77
Employees	91573	Current Ratio	1.21	Sales Q/Q	-13.36%	Oper. Margin	22.55%	RSI (14)	43.33	Volatility	1.20% 1.20%
Optionable	Yes	Debt/Eq	0.29	EPS Q/Q	-	Profit Margin	19.77%	Rel Volume	0.65	Prev Close	46.06
Shortable	Yes	LT Debt/Eq	0.22	Earnings	Oct 27 BMO	Payout	39.20%	Avg Volume	2.06M	Price	46.32
Recom	2.00	SMA20	-0.20%	SMA50	-5.88%	SMA200	-10.73%	Volume	1,334,100	Change	0.56%

Date	Action	Analyst	Rating Change
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
Sep-20-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-03-19	Initiated	Bernstein	Outperform

Show Previous Ratings

Dec-09-23 09:48PM	25 Most Valuable European Companies Heading into 2024 (Insider Monkey)
Dec-08-23 03:19AM	Analyst Report: Sanofi (Morningstar Research)
Dec-07-23 03:54PM	UPDATE 2-US urges makers of infant RSV shots to meet winter demand (Reuters)
03:16PM	Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus (Zacks)
11:04AM	US urges RSV vaccine makers to meet winter demand, White House says (Reuters)
09:59AM	Loading…
09:59AM	Sanofi: chief must prove he can win R&D game (Financial Times)
09:05AM	Sanofi CEO Paul Hudson on R (CNBC TV)
07:43AM	Sanofi to boost drug development spend by 700 mln euros in 2024 (Reuters)
06:38AM	Sanofi, facing skeptical investors, predicts $5B sales for 3 drugs, names 9 more blockbusters (FierceBiotech.com)
04:56AM	UPDATE 2-European shares slip after recent rally, economic worries weigh (Reuters)
02:31AM	UPDATE 2-Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline (Reuters)
01:35AM	Press Release: Sarclisa (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant (GlobeNewswire)
Dec-06-23 10:28PM	REFILE-UPDATE 1-Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline (Reuters)
09:40PM	Sanofi expects nearly $11 bln in annual sales from pharma assets by 2030 (Reuters)
09:30PM	Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology (GlobeNewswire)
04:24AM	Loading…
04:24AM	Merck KGaA Plunges as Multiple Sclerosis Drug Fails in Trial (Bloomberg)
Dec-05-23 05:03PM	UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials (Reuters)
07:24AM	Sanofi spins up AI pact, inking $140M deal to apply Aqemia's physics algorithms to drug discovery (FierceBiotech.com)
Nov-30-23 11:04AM	UPDATE 1-Turkey launches investigation into 19 pharma companies (Reuters)
08:30AM	Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment (Business Wire)
08:30AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
02:13AM	Turkey launches investigation into 19 pharma companies (Reuters)
Nov-28-23 10:25AM	UPDATE 2-White House urges RSV immunization makers to meet demand (Reuters)
Nov-27-23 04:27PM	Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales (Investor's Business Daily)
02:29PM	How the high-stakes world of Formula 1 racing inspired Sanofi CEO Paul Hudson to deliver more medicines (Fortune)
06:00AM	Regeneron, Sanofi to seek new Dupixent approval in US after COPD success (BioPharma Dive)
01:30AM	Press Release: Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease (GlobeNewswire)
01:30AM	Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease (GlobeNewswire)
Nov-26-23 03:11PM	12 Best Diabetes Stocks To Buy Now (Insider Monkey)
Nov-25-23 07:30AM	3 Top Dividend Champions With Market-Beating Yields (TheStreet.com)
12:00PM	Loading…
Nov-23-23 12:00PM	Sanofi: Information concerning the total number of voting rights and shares - October 2023 (GlobeNewswire)
Nov-21-23 03:20PM	A Golden Age of Vaccines Is Here. What It Means for You. (Barrons.com)
Nov-20-23 06:52AM	20 Most Valuable Healthcare Companies in the World (Insider Monkey)
Nov-16-23 02:20PM	CORRECTED-UPDATE 2-CDC expedites release of 77,000 additional doses of Sanofi-AstraZeneca's RSV drug (Reuters)
02:10PM	CORRECTED-CDC expedites release of 77,000 additional doses of Sanofi-AstraZeneca's RSV drug (Reuters)
03:03AM	Sanofi Taps Adviser for OTC Spinoff as Buyout Firms Circle (Bloomberg)
Nov-15-23 10:36AM	Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:00AM	Biotech raises funds to find cancer treatments using transgenic mice (Financial Times)
Nov-14-23 07:21PM	MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress (GuruFocus.com)
Nov-10-23 02:18PM	AstraZeneca prioritizes US for RSV drug amid surge in cases (Reuters)
09:57AM	Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs (Healthcare Dive)
05:30AM	How AI-enabled KPIs can help leaders align their companiesand get better results (Fortune)
01:24AM	Q3 2023 Exscientia PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 08:48AM	Q3 2023 Ligand Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 02:15PM	Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-07-23 07:14PM	PRESS DIGEST- Financial Times - Nov. 8 (Reuters)
11:42AM	Sanofi Probed for Market Manipulation by French Authorities (Bloomberg)
08:55AM	French prosecutors examine claims of market manipulation against Sanofi (Financial Times)
05:55AM	UPDATE 1-French prosecutors probe Sanofi over possible market manipulation -source (Reuters)
Nov-06-23 04:01PM	Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi (Investor's Business Daily)
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 10:07AM	This Stock Just Dropped By 15%: Is It a Buy? (Motley Fool)
Nov-02-23 12:31PM	Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline (Zacks)
12:15PM	Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities (PR Newswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
Nov-01-23 08:30AM	Get Ready for Next Generation of Diabetes, Weight-Management Drugs (PR Newswire)
07:00AM	Sanofi launches 'The 1 Pledge' movement to drive early screening for type 1 diabetes in the U.S. (PR Newswire)
Oct-31-23 12:15PM	Sanofi pays $30M for first look at MeiraGTx's data and a shot to brew up deals (FierceBiotech.com)
Oct-30-23 04:35PM	13 Most Undervalued Pharma Stocks To Buy According To Analysts (Insider Monkey)
11:04AM	Sanofi stock recovers slightly after last week's plunge (Yahoo Finance Video)
08:44AM	AbbVie shares rise after Barclays upgrades rating of U.S. drugmaker (Investing.com)
08:25AM	Sanofi invests in MeiraGTx and its gene-regulating technology (BioPharma Dive)
05:30AM	Sanofi and Insight Enterprises CEOs: With the right blueprint in place, AI will empower workers and help big companies become more nimble (Fortune)
Oct-29-23 03:02PM	Sanofi (NASDAQ:SNY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 04:03PM	Sanofi Stock Crashes 19% As Drugmaker's Third Quarter Comes In Light Ahead Of Spinoff (Investor's Business Daily) -19.13%
03:44PM	Ford forecast, Sanofi, Juniper Networks: Top Stocks (Yahoo Finance Video)
03:30PM	Sanofi (SNY) Q3 2023 Earnings Call Transcript (Motley Fool)
02:24PM	Why Drug Companies Dont Want to Sell Allergy Medicines and Bandages Anymore (The Wall Street Journal)
01:59PM	Sanofis Lousy Outlook Is Bruising Its Stockand Shocking Pharma Investors (The Wall Street Journal)
11:37AM	Sanofi Will Spin Out Its Consumer Health Division and 2024 Guidance Disappoints. The Stock Is Diving. (Barrons.com)
11:33AM	Sanofi shares fall more than 19% after cut to profit outlook (Financial Times)
11:33AM	Sanofi shares fall 19% after cut to profit outlook (Financial Times)
11:29AM	Analyst Report: Sanofi (Morningstar Research)
11:15AM	Sanofi CEO Shocks Investors With Investment Plan, Few Details (Bloomberg)
10:18AM	Stocks to Watch Friday: Exxon, Amazon, Chevron, Intel, Enphase (The Wall Street Journal)
10:18AM	Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit (Zacks)
10:05AM	Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products (Zacks)
09:53AM	Sanofi CEO says he is opting against 2025 market certainty to create long-term value (Reuters)
09:25AM	SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff (InvestorPlace)
09:03AM	Sanofi Crashes 16% As Third Quarter Comes In Light Ahead Of Spinoff (Investor's Business Daily)
08:58AM	Sanofi CEO Paul Hudson on Q3 results: Increased R (CNBC TV)
08:37AM	Regeneron (REGN) to Report Q3 Earnings: What's in the Cards? (Zacks)
07:17AM	Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips (RTT News)
06:10AM	Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts (FierceBiotech.com)
05:32AM	Sanofi: Q3 Earnings Snapshot (Associated Press Finance)
05:01AM	UPDATE 1-French shares lag European peers on Sanofi's downbeat forecast (Reuters)
04:24AM	Sanofi shares sink on lower profit outlook and consumer unit split (Financial Times)
04:24AM	Sanofi shares fall on lower profit outlook (Financial Times)
04:03AM	Sanofi Plans to Spin Off Consumer-Healthcare, Pharma Businesses (The Wall Street Journal)
02:00AM	UPDATE 5-Sanofi loses $21 bln in market value after dropping 2025 profit target (Reuters)
01:31AM	Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results (GlobeNewswire)
01:30AM	Sanofi: considering consumer unit listing from late next year (Reuters)
01:30AM	Sanofi Will Carve Out Consumer Health Division in Bid to Invest More in Science (Barrons.com)
01:30AM	Press Release: Sanofi Enters Next Chapter of Play to Win Strategy (GlobeNewswire)
Oct-24-23 05:44PM	Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch (Investor's Business Daily)
08:45AM	Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments (PR Newswire)
Oct-23-23 04:04PM	Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout (Investor's Business Daily)
09:28AM	Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space (Investor's Business Daily)
Oct-22-23 03:00PM	Press Release: Dupixent (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) (GlobeNewswire)
02:59PM	Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE) (GlobeNewswire)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience